-+ 0.00%
-+ 0.00%
-+ 0.00%

BriaCell plans Bria-OTS+ clinical entry in metastatic breast, prostate cancers later this year

PUBT·04/21/2026 11:31:19
Listen to the news
BriaCell plans Bria-OTS+ clinical entry in metastatic breast, prostate cancers later this year
  • BriaCell presented positive preclinical data on Bria-OTS+ at 2026 AACR Annual Meeting on April 21, 2026.
  • Bria-OTS+ showed broad anti-cancer activity in lab models, activating immune responses with durable tumor-killing effects.
  • Program advanced toward first clinical entry in metastatic breast cancer and prostate cancer later in 2026.
  • Company outlined plans to expand Bria-OTS+ into lung cancer and melanoma indications in 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Briacell Therapeutics Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604210730PRIMZONEFULLFEED9693580) on April 21, 2026, and is solely responsible for the information contained therein.